Samsung Biologics has announced its acquisition of Polypeptide Group for approximately 2.7 trillion won, marking the largest M&A deal in Korea’s pharmaceutical and biotech sector. This acquisition aims to expand Samsung’s foothold in the rapidly growing peptide market, essential for obesity and diabetes treatments. Polypeptide, a leading global CDMO, will enhance Samsung’s production capabilities with its established facilities in the U.S., Europe, and India. The deal is expected to be finalized by the end of the year, pending regulatory approvals, and will allow Samsung to leverage Polypeptide’s expertise to address the rising demand for glucagon-like peptide-1 therapies.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.asiae.co.kr/en/article/2026072009210183660
